Concepedia

Noel M. Thomsen

NM

Statistics

Publications

6

Citations

453

H-Index

6

Active since

2017

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Novartis (China)

Duke University

Noel M. Thomsen is an author at Novartis (United States) specializing in drug design, drug discovery, and medicinal chemistry.

Publications per year

2017–2024

6

Publications

6

Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy

Simone Bonazzi, Eva d’Hennezel, Rohan E. J. Beckwith et al. · Cell chemical biology · 2023 · 156 citations · Full text

, , +14

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

George S. Tria, Tinya J. Abrams, Jason R. Baird et al. · Journal of Medicinal Chemistry · 2018 · 125 citations · Full text

, , +16

A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction

Pamela Y. Ting, Sneha Borikar, John Ryan Kerrigan et al. · Science · 2024 · 85 citations

, , +12

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

Heather Burks, Tinya J. Abrams, C.A. Kirby et al. · Journal of Medicinal Chemistry · 2017 · 42 citations · Full text

, , +17

Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders

Simone Bonazzi, Carleton P. Goold, Audrey Gray et al. · Journal of Medicinal Chemistry · 2020 · 32 citations · Full text

, , +14

1–5 of 6